Product Description: Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022.
CAS Number: 2639481-06-2
Molecular Weight: N/A
Research Area: Cancer
Solubility: H2O
Target: PD-1/PD-L1